drugset
drugset / Trial / NCT07551583

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

NCT07551583 ↗

Phase 2 Not yet recruiting 15 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.

Timeline

Start
2026-10-01
Primary completion
2030-12-31
Completion
2032-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule — Intravenous
Subject Doxorubicin Other / unclassified — Intravenous
Subject Nivolumab Monoclonal antibody — Intravenous
Subject Vinblastine Small molecule — Intravenous

Indications

Hodgkins lymphoma